View Article


The most frequent modifiable risk factor for death and disability is hypertension. Other modifiable risk factors include stroke, accelerated coronary and systemic atherosclerosis, heart failure, chronic kidney disease, lowering blood pressure with antihypertensive medications, and lowering the prevalence of cardiovascular disease. The 2017 American college of cardiology (ACC)/American heart association (AHA) hypertension recommendations define hypertension as systolic blood pressure (BP) greater than 130 mmHg or diastolic blood pressure (BP) less than 80 mmHg. In patients with CHD, CHF, following kidney transplantation, diabetes mellitus, and stroke, BP should be less than 130/80 mmHg. The patient was advised to modify their lifestyle by reducing their salt intake, losing weight if they were overweight, exercising regularly, drinking alcohol in moderation, and consuming more potassium-rich foods. The first antihypertensive medication should often come from one of the four types listed below: calcium channel blockers, thiazide diuretics, ACE inhibitors, and ARBs. These drugs have been found to lower cardiovascular events. Renal denervation and baroreflex activation therapy are the two interventional methods utilised in clinical practise to treat a variety of treatment-resistant hypertensions. Carotid body ablation and the implantation of an AVF are two other interventional techniques, although none of them can stop the progression of cardiovascular disease or a hypertensive patient's mortality.


Target Blood Pressure, Carotid Body Ablation Therapy, Renal Denervation, and Antihypertensive Drug Therapy


  1. 2017 Whelton, P.K., et al. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA). American College of Cardiology Journal, 71, e127–e248. 
  2. Muntner, P., et al. (2018) Potential Impact of the 2017 ACC/AHA High Blood Pressure Guideline on the US Population. 109–118. In circulation, 137. 
  3. S.S. Lim and others, 3. (2012) A Systematic Analysis for the 2010 Global Burden of Disease Study: Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990–2010. 380, 2224-2260, Lancet. 
  4. David Lloyd-Jones et al. (2009) A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart Disease and Stroke Statistics—2009 Update. 119, 480–486, circulation. 
  5. A Propensity-Matched Study of the Association of Peripheral Arterial Disease with Cardiovascular Outcomes in Community-Dwelling Older Adults, Aronow, W.S., et al. Journal of American College of Cardiology, 103, 130–135. 
  6. W. S. Aronow et al. (2011) ACCF/AHA A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, 2011 Expert Consensus Document on Hypertension in the Elderly. 123, 2434–2506 of circulation. 
  7. Prevalence of Resistant Hypertension in the United States, 2003–2008. Persell, S.D. 1076–1080 in Hypertension, 57. 
  8. Sim, J.J., et al. Resistant Hypertension in a Large, Ethnically Diverse Hypertension Population in an Integrated Health System: Characteristics of Resistant Hypertension. Mayo Clinic Proceedings, 88, 1099–1107.
  9. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension, 63, 451-458. Calhoun, D.A., et al. 
  10. High Rates of Non-Adherence to Antihypertensive Treatment Revealed by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HP LC-MS/MS) Urine Analysis, Tomaszewski, M., et al. (2014). Heart, 100, 855-861. 
  11. J. Ceral et al. (2011) Arterial hypertension that is challenging to control or uncooperative patients? The evaluation of serum antihypertensive drug concentrations to distinguish between non-responsiveness and non-adherence to advised therapy. 34, 87–90, Hypertension Research. 
  12. Resistant Hypertension? 12. Jung, O., et al. Analyzing Adherence Using Toxicological Urine. 31, 766-774, Journal of Hypertension. 
  13. Therapeutic Drug Monitoring Facilitates Blood Pressure Control in Resistant Hypertension, S. Brinker et al. (2014). American College of Cardiology Journal, 63, 834–835. 
  14. Ettehad, D., et al., "Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis," Lancet, 387, 957-967 (2016). 
  15. A Randomized Trial of Intensive vs Standard Blood-Pressure Control, Wright Jr., J.T., et al. (2015). 373, 2103-2116; New England Journal of Medicine. 
  16. James, P.A., et al. (2014) Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311, 507-520. 
  17. Ogedegbe, G., Lackland, D.T., Wright Jr., J.T., Fine, L.J., and Dennison Himmelfarb, C.R. (2014) The Minority View on the Evidence for a Systolic Blood Pressure Goal of Less than 150 mmHg in Patients Aged 60 Years or Older. Internal Medicine Annals, 160(4):499-503. 
  18. NICE Guideline on Hypertension, Jaques, H. 34, 406-408, European Heart Journal. 
  19. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension, published by the M.A. Weber et al. group in 2014. 16, 14–26, Journal of Clinical Hypertension. 
  20. The American Heart Association, American College of Cardiology, and American Society of Hypertension (2015) Treatment of Hypertension in Patients with Coronary Artery Disease: A Scientific Statement. 20. Rosendorff, C., et al. American College of Cardiology Journal, 65, 1998-2038. 
  21. Guideline for the Diagnosis and Management of Hypertension in Adults—2016, G.M. Gabb et al., Medical Journal of Australia, 205, 85–89. 
  22. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. 22. Qaseem, A., et al. 166, 430-437, Annals of Internal Medicine. 
  23. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Whelton, P.K., Carey, R.M., Aronow, W.S., Casey Jr., D.E. e13–e115 in Hypertension. 
  24. (2017) Lifestyle Measures for Treating Hypertension. Aronow, W.S. 12, 1241–1243, Archives of Medical Science. 
  25. Thompson, A.M. et al., "Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events among Persons without Hypertension: A Meta-Analysis," 2011. JAMA, 305, 913-922. 
  26. The Effects of Blood Pressure Reduction and of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events according to Baseline Blood Pressure: Meta-Analysis of Randomized Trials, S. Czernichow et al., 2011, p. 26. 29, 4-16 of the Journal of Hypertension. 
  27. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report, Goff Jr., D.C., et al. American College of Cardiology Journal, 63, 2935–2959. 
  28. Intensive versus Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged 75 Years: A Randomized Clinical Trial, Williamson, J.D., et al. (2016). JAMA, 315, 2673-2682. 
  29. The Collaboration of Blood Pressure Lowering Treatment Trialists (2014) A meta-analysis of patient data on blood pressure-lowering therapy based on cardiovascular risk. The Lancet 384(5):591–598. 
  30. Lewington, S., et al., "A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies: Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality." The Lancet, 360, from 1903 to 1913. 
  31. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis, Bundy, J.D., et al. 2017, 31. 775-781 in JAMA Cardiology. 
  32. 2017 ACC/AHA/HFSA, Yancy, C.W., et al. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. American College of Cardiology Journal, 70, 776–803. 
  33. Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier, by A. Upadhyay, A. Earley, S. M. Haynes, and K. Uhlig. Internal Medicine Annals, 154, 541-548. 
  34. Blood-Pressure Targets in Patients with Recent Lacunar Stroke: The SPS3 Randomized Trial, O.R. Benavente et al., 2013. 507–515 in The Lancet, 382. 
  35. (2015) Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Emdin, C.A., et al. JAMA, 313, 603-615. 
  36. Orthostatic Hypotension in Diabetics in the ACCORD. 36. Aronow, W.S. (Action to Control Cardiovascular Risk in Diabetes) Test of blood pressure. 851–852 in Hypertension, 68. 
  37. Wang, W.T., et al. (2016) Traditional and Bayesian Network Meta-Analysis of Randomized Trials: Comparative Effectiveness of Blood Pressure-Lowering Drugs in Patients Who Have Already Suffered from Stroke. 95, e3302 in medicine. 
  38. Obstructive sleep apnea is the most prevalent secondary cause of hypertension associated with resistant hypertension, according to Pedrosa, R.P., et al. 811–817 in Hypertension, 58. 
  39. Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity. Schwartz, G.L. and Turner, S.T. 2005. 51, 386-394, Clinical Chemistry. 
  40. A Comparison of Biochemical Tests for Pheochromocytoma: Measurement of Fractionated Plasma Metanephrines Compared with the Combination of 24-Hour Urinary Metanephrines and Catecholamines. Sawka, A.M., Jaeschke, R., Singh, R.J., and Young, W.F. 2003. 88, 553-558, Journal of Clinical Endocrinology and Metabolism. 
  41. A. Oliveras et al. (2010) found that true resistant hypertension is associated with urinary albumin excretion. 24, 27–33, Journal of Human Hypertension.
  42. Resistant Hypertension: Diagnosis, Evaluation, and Treatment, D.A. Calhoun et al., 2008. A Scientific Statement from the Council for High Blood Pressure Research and the American Heart Association Professional Education Committee. 51: 1403–1419 in Hypertension. 
  43. Clinical Differences between Resistant Hypertensives and Patients Treated and Controlled with Three or Less Drugs, De la Sierra, A., et al. (2012). 30, 1211–16, Journal of Hypertension. 
  44. Campese, V.M., N. Mitra, and D. Sandee, "Hypertension in Renal Parenchymal Disease: Why Is It So Resistant to Treatment" (2006). 69, 967-973, Kidney International. 
  45. Effect of Lower Sodium Intake on Health: Systematic Review and Meta-Analyses. N. J. Aburto et al. BMJ, 346, f1326. 
  46. He, F.J., Li, J. and Macgregor, G.A. (2013) Effect of Longer Term Modest Salt Reduction on Blood Pressure: Cochrane Systematic Review and Meta-Analysis of Randomised Trials. BMJ, 346, f1325. 
  47. (2003) Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Neter, J.E., et al. 878–884 in Hypertension, 42. 
  48. Exercise Training for Blood Pressure: A Systematic Review and Meta-Analysis, by Cornelissen, V.A., and Smart, N.A. (2013). doi:10.1161/JAHA.112.004473 Journal of the American Heart Association, 2(e004473). 
  49. (2014) Isometric Exercise Training for Blood Pressure Management: A Systematic Review and Meta-Analysis. Carlson, D.J., et al. Proceedings of the Mayo Clinic, 89, 327-334. 
  50. Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials, Xin, X., et al., 2001. 38, 1112-1127. Hypertension. 
  51. The impact of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis, Roerecke, M., et al., 2017. e108–e120 in Lancet Public Health, 2. 
  52. Effects of Oral Potassium on Blood Pressure. Whelton, P.K., et al. Randomized Controlled Clinical Trials Meta-Analysis. JAMA, 277, 1624-1632.
  53. Major Outcomes in High-Risk Hypertensive Patients from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) Rando-mized to Calcium Channel Blocker vs. Diuretic vs. Angiotensin-Converting Enzyme Inhibitor:. JAMA, 288, 2981–2997 (DOI: 10.1001/jama.288.23.2981). 
  54. Law, M.R., Morris, J.K., and Wald, N.J. (2009). "Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Meta-Analysis of 147 Randomised Trials in the Context of Expectations from Prospective Epidemiological Studies." BMJ, 338, b1665. 
  55. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update, Smith Jr., SC, et al. a recommendation from the American College of Cardiology Foundation and the American Heart Association. 124, 2458–2473; circulation. 
  56. (2006) Current Role of Beta-Blockers in the Treatment of Hypertension. 56. Aronow, W.S. 11, 2599–2607, Expert Opinion on Pharmacotherapy. 
  57. Pitt, B., et al., 57. (2005) In patients with acute myocardial infarction and left ventricular systolic dysfunction, eplerenone decreases mortality 30 days after randomization. American College of Cardiology Journal, 46, 425-431. 
  58. Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure, MERIT-HF Study Group (1999). (MERIT-HF). The Lancet, 353, from 2001 to 2007. 
  59. Effect of Carvedilol on Survival in Severe Chronic Heart Failure, Packer, M., et al. (2001). 344, 1651-1658, New England Journal of Medicine. 
  60. Investigators and Committees for CIBIS-II at 60 (1999) A Randomized Trial of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). pp. 9–13 in The Lancet 353. 
  61. (1997) Effect of Propranolol versus No Propranolol on Total Mortality Plus Nonfatal Myocardial Infarction in Older Patients with Prior Myocardial Infarction, Congestive Heart Failure, and Left Ventricular Ejection Fraction  40% Treated with Diuretics Plus Angiotensin-Converting Enzyme Inhibitors. American Journal of Cardiology, 1980, 80, 207–209. 
  62. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial, M.A. Pfeffer et al. (2015), 62. 34–42. In circulation, 131. 
  63. J.T. Wright Jr., et al., "Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results from the AASK Trial," 2002. JAMA, 288, 2421-2431. 
  64. T.H. Jafar et al., "Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis," 2003. Internal Medicine Annals, 139, 244–252. 
  65. Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease, L.J. Appel et al. (2010). 363: 918-929 in the New England Journal of Medicine. 
  66. Antihypertensives for Kidney Transplant Recipients: Systematic Review and Meta-Analysis of Randomized Controlled Trials, Cross, N.B., et al., 2009. 88:7–18 in Transplantation. 
  67. The PROGRESS Collaborative Group (2001) Randomized Trial of a Perindopril-Based Blood-Pressure-Lowering Regimen Among 6,105 Patients with a History of Stroke or Transient Ischaemic Attack. 1033–1041 in The Lancet, 358. 
  68. L. Liu et al., "Blood Pressure Reduction for the Secondary Prevention of Stroke: A Chinese Trial and a Systematic Review of the Literature," (2009). Research on hypertension, 32, 1032–1040. 
  69. Lakhan, S.E., and Sapko, M.T. (2009) A Systematic Review and Meta-Analysis of Blood Pressure Lowering Treatment for Preventing Stroke Recurrence. international medical archives, 2, 30. 
  70. Outcomes Among Hypertensive Patients with Concomitant Peripheral and Coronary Artery Disease: Findings from the International VErapamil-SR/Trandolapril Study, Hypertension, 55, 48–53, 2010.
  71. F. Turnbull et al. (2005) Results of Prospectively Designed Reviews of Randomized Trials: Impact of Various Blood Pressure-Lowering Regimens on Major Cardiovascular Events in People with and Without Diabetes Mellitus. 165:1410-1419, Internal Medicine Archives. 
  72. Comparative Efficacy and Safety of Blood Pressure-Lowering Agents in Adults with Diabetes and Kidney Disease: A Network Meta-Analysis. Palmer, S.C., et al. The Lancet 385:2047–2056. 
  73. Renin-Angiotensin System and Cardiovascular Risk by R.E. Schmieder et al. doi:10.1016/S0140-6736(07)60242-6 The Lancet, 369, 1208–1219. 
  74. (2012) Type-Selective Benefits of Drugs in the Treatment of Acute Aortic Dissection. Suzuki, T., et al. (from the International Registry of Acute Aortic Dissection [IRAD]). 109, 122-127, American Journal of Cardiology. 
  75. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Women of Childbearing Age: Risks vs Benefits, Pucci, M., et al. (2015). 22, 221-231 in Expert Review of Clinical Pharmacology. 
  76. (2000) Management of Mild Chronic Hypertension during Pregnancy: A Review. Ferrer, R.L. Obesity and gynecology, 96, 849–860. 
  77. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, Moretti, M.E., et al. (2012). International Journal of Obstetrics and Gynecology, 2012, Article ID: 658310. 
  78. (2004) Management of Hypertension Before, During, and After Pregnancy. James, P.R. and Nelson-Piercy, C. Heart, 90, 1499–1504 
  79. A Systematic Review of Add-On Pharmacologic Therapy in the Treatment of Resistant Hypertension, Tataru, A.P. and Barry, A.R. 2017, p. 79. 311-318. American Journal of Cardiovascular Drugs. 
  80. Aldosterone, Hypertension, and cardiovascular disease: An Endless Story, L.M. Ruilope, 2008. 52, 207–208. Hypertension. 
  81. Kawamoto, T., and others, 81. (1992) The function of steroid 11 beta-hydroxylase and steroid 18 hydroxylase in human glucocorticoids and mineralocorticoids biosynthesis. United States of America, Proceedings of the National Academy of Sciences, 89, 1458–1462. 
  82. J. Fagart, et al., "82" (2010) A Potent and Selected Nonsteroidal Molecule's New Mode of Mineralocorticoid Receptor Antagonism. 285, 29932-29940, Journal of Biological Chemistry. 
  83. 2012 saw the discovery of BAY 94-8862, a non-steroidal mineralocorticoid receptor antagonist used to treat cardiorenal diseases. ChemMedChem, 7, 1385–1403, Barfacker, L., et al., 
  84. Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects against Rat Cardiorenal Injury, Kolkhof, P., et al. (2014). 64, 69–78, Journal of Cardiovascular Pharmacology. 
  85. Investigation of Aldosterone-Synthase Inhibition in Rats. Menard, J., Marie-Françoise, G., Thanh-Tam, G., and Alvine, B. 2006. 24:1147–1155. Journal of Hypertension. 
  86. Aldosterone Antagonism or Synthase Inhibition Reduces End-Organ Damage Induced by Treatment with Angiotensin and High Salt, Lea, W.B., et al., 2009, p. 86. 75, 936–944 of Kidney International. 
  87. Aldosterone Synthase Inhibition: Cardiorenal Protection in Animal Disease Models and Translation of Hormonal Effects to Human Subjects, Menard, J., et al. (2014). 12, 340. Journal of Translational Medicine.
  88. Aldosterone Synthase Inhibition with LCI699: A Proof-of-Concept Study in Patients with Primary Aldosteronism, L. Amar et al. (2010). 831–838. Hypertension, 56. 
  89. (2011) Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial. Calhoun, D.A., et al. 124 circulation from 1945 to 1955. 
  90. Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease by Corti, R., Burnett Jr., J.C., Rouleau, J.L., Ruschitzka, and Lüscher, T.F. publication number 104, 1856–1862. 
  91. Chen, X.M., Vengurlekar, S.S., Silvester, K.R., Makhlina, M., et al. (2013) The in vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide that is a natriuretic peptide receptor-A antagonist and bronchodilator that is resistant to neutral endopeptidase. 229–238 in Pulmonary Pharmacology and Therapeutics. 
  92. Almeida, L., et al. (2013) Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat, a Novel Dopamine Beta-Hydroxylase Inhibitor in Patients with Hypertension. 35 years of Clinical Therapeutics, 1983 to 1996. 
  93. Esler, M., et al., "Assessment of Human Sympathetic Nervous System Activity from Measurements of Norepinephrine Turnover," 1988. 11, 3-20. Hypertension.
  94. Neural Control of Renal Function, G.F. DiBona and U.C. Kopp, 1997. 77, 75–197, Physiological Reviews. 
  95. Esler, M.D., et al. 95. (2010) A Randomized Controlled Trial of Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial). The Lancet, vol. 376, pp. 1903–1909. 
  96. R. E. Schmieder et al. (2012) ESH Renal denervation as an interventional therapy for resistant hypertension, position paper. 30, 837-841, Journal of Hypertension. 
  97. Baroreflex Activation Therapy reduces Blood Pressure in Patients with Resistant Hypertension: Results from the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial, by J.D. Bisognano et al. (2011). American College of Cardiology Journal, 58, 765-773. 
  98. Scheffers, I.J., et al., Novel Baroreflex Activation Therapy in Resistant Hypertension: Results of a European Multi-Center Feasibility Study, 2010. American College of Cardiology Journal, 56, 1254–1258. 
  99. Tonic Carotid Body Chemoreceptor Activity Contributes to the Increased Sympathetic Drive in Essential Hypertension, according to Sinski, M., et al. (2012). 35, 487-491, Hypertension Research. 
  100. A.E. Burchell, M.D. Lobo, N. Sulke, P.A. Sobotka, and J.F.R. Paton. (2014) Is Arteriovenous Anastomosis the Best Method for Managing Hypertension? 64, 6, and 12 for hypertension. 
  101. Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired Renal Function: A Randomized Trial, Bax, L., et al., 2009. 150, 840-848, Annals of Internal Medicine. 
  102. Revascularization vs medical therapy for renal-arterial stenosis. Wheatley, K., et al., 2009. 361 (1953–1962) New England Journal of Medicine.

Varsha Pangale
Corresponding author

Department of Pharmaceutical Quality Assurance, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

Neha Gaikwad

Department of Pharmaceutical Quality Assurance, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

Samiksha Aher

Department of Pharmaceutical Quality Assurance, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

Varsha Pangale*, Neha Gaikwad, Samiksha Aher, A systematic review on Hypertension and conditions related to thereof, Int. J. in Pharm. Sci., 2024, Vol 1, Issue 4, 166-185.

More related articles
Preparation And Evaluation Of Polyherbal Antacid P...
Mr. Akash D. Surve , Pooja K. Khanzode, Prathamesh S. Shinde, S...
A Review On Novel Excipients...
Vaibhav B. Gunjal, Darshan S. Sonawane, Samruddhi K. Ahire, Prana...
Effect Of Gmelina Arborea Roxb. Bark Extract On Li...
Rohit K. Kaswala, Jagdish V. Kamath, Manodeep Chakraborty, ...
Nanobots in Medicine ...
Iranna B. Gulagonda, Dhiraj D. Mane, Sanjay L. Dhavale, Vishal K. Mote, Rahul A. Kedar, ...
A Review On: Herbal Hair Serum...
Mr.Prashant Sopan Dhonde , Mr. Vishal Shivaji Gaikwad, ...
A Comparative Study of Ketorolac, Paracetamol and Tramadol for Post Operative Pa...
Syed Jaffer, Shaista Sumayya, Meraj fatima, Safa mehboobunnisa siddiqi, Ruqshan Nazneen, ...
Related Articles
Innovative Strategies in Pharmaceutical Sciences: Exploring the Potential of Dru...
Deep Lokraj Selokar, Suraj Nirwan, Gajanan Sormare, Dinesh Biyani, Dhiraj Dhabade, Milind Umekar, ...
Review About Histopathological Effects Of Ibuprofen Drug On Bones And Cartilages...
Eftikhaar hasan kadhum, Teeba T.Khudair, Dmoaa Majid Nasar, ...
A Review: Natural Anti-Obesity Agents...
Yashraj Narake, Omkar Gongane, Tejas Kapase , Pritam Salokhe, Sachin Navale, Nilesh Chougule, ...
A Comprehensive Review On Herbal Plants Showing Anti Diabetic Activity...
Saurabh Dumbre, Gaurav Gawade, Swati Jadhav, Pravin Khamkar, ...
Preparation And Evaluation Of Polyherbal Antacid Powder...
Mr. Akash D. Surve , Pooja K. Khanzode, Prathamesh S. Shinde, Samiksha M. Pakhare, Shyam G. Rekhe,...
More related articles
Preparation And Evaluation Of Polyherbal Antacid Powder...
Mr. Akash D. Surve , Pooja K. Khanzode, Prathamesh S. Shinde, Samiksha M. Pakhare, Shyam G. Rekhe,...
A Review On Novel Excipients...
Vaibhav B. Gunjal, Darshan S. Sonawane, Samruddhi K. Ahire, Pranav K. Jadhav, Yashashri K. Deore, Sh...
Effect Of Gmelina Arborea Roxb. Bark Extract On Liver Cells...
Rohit K. Kaswala, Jagdish V. Kamath, Manodeep Chakraborty, ...
Preparation And Evaluation Of Polyherbal Antacid Powder...
Mr. Akash D. Surve , Pooja K. Khanzode, Prathamesh S. Shinde, Samiksha M. Pakhare, Shyam G. Rekhe,...
A Review On Novel Excipients...
Vaibhav B. Gunjal, Darshan S. Sonawane, Samruddhi K. Ahire, Pranav K. Jadhav, Yashashri K. Deore, Sh...
Effect Of Gmelina Arborea Roxb. Bark Extract On Liver Cells...
Rohit K. Kaswala, Jagdish V. Kamath, Manodeep Chakraborty, ...